297 related articles for article (PubMed ID: 17517626)
1. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
Valmori D; Souleimanian NE; Tosello V; Bhardwaj N; Adams S; O'Neill D; Pavlick A; Escalon JB; Cruz CM; Angiulli A; Angiulli F; Mears G; Vogel SM; Pan L; Jungbluth AA; Hoffmann EW; Venhaus R; Ritter G; Old LJ; Ayyoub M
Proc Natl Acad Sci U S A; 2007 May; 104(21):8947-52. PubMed ID: 17517626
[TBL] [Abstract][Full Text] [Related]
2. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
[TBL] [Abstract][Full Text] [Related]
3. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
5. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
Tsuji T; Sabbatini P; Jungbluth AA; Ritter E; Pan L; Ritter G; Ferran L; Spriggs D; Salazar AM; Gnjatic S
Cancer Immunol Res; 2013 Nov; 1(5):340-50. PubMed ID: 24777970
[TBL] [Abstract][Full Text] [Related]
6. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Fourcade J; Kudela P; Andrade Filho PA; Janjic B; Land SR; Sander C; Krieg A; Donnenberg A; Shen H; Kirkwood JM; Zarour HM
J Immunother; 2008 Oct; 31(8):781-91. PubMed ID: 18779741
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
Diefenbach CS; Gnjatic S; Sabbatini P; Aghajanian C; Hensley ML; Spriggs DR; Iasonos A; Lee H; Dupont B; Pezzulli S; Jungbluth AA; Old LJ; Dupont J
Clin Cancer Res; 2008 May; 14(9):2740-8. PubMed ID: 18451240
[TBL] [Abstract][Full Text] [Related]
8. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
[TBL] [Abstract][Full Text] [Related]
10. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
[TBL] [Abstract][Full Text] [Related]
11. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients.
Karbach J; Neumann A; Atmaca A; Wahle C; Brand K; von Boehmer L; Knuth A; Bender A; Ritter G; Old LJ; Jäger E
Clin Cancer Res; 2011 Feb; 17(4):861-70. PubMed ID: 21163871
[TBL] [Abstract][Full Text] [Related]
12. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.
Mischo A; Bubel N; Cebon JS; Samaras P; Petrausch U; Stenner-Liewen F; Schaefer NG; Kubuschok B; Renner C; Wadle A
Int J Oncol; 2011 Jul; 39(1):287-94. PubMed ID: 21573493
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
14. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
[TBL] [Abstract][Full Text] [Related]
15. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
16. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
[TBL] [Abstract][Full Text] [Related]
18. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
Nishikawa H; Sato E; Briones G; Chen LM; Matsuo M; Nagata Y; Ritter G; Jäger E; Nomura H; Kondo S; Tawara I; Kato T; Shiku H; Old LJ; Galán JE; Gnjatic S
J Clin Invest; 2006 Jul; 116(7):1946-54. PubMed ID: 16794737
[TBL] [Abstract][Full Text] [Related]
19. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
Uenaka A; Wada H; Isobe M; Saika T; Tsuji K; Sato E; Sato S; Noguchi Y; Kawabata R; Yasuda T; Doki Y; Kumon H; Iwatsuki K; Shiku H; Monden M; Jungbluth AA; Ritter G; Murphy R; Hoffman E; Old LJ; Nakayama E
Cancer Immun; 2007 Apr; 7():9. PubMed ID: 17441676
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
